0001127602-21-010127.txt : 20210310 0001127602-21-010127.hdr.sgml : 20210310 20210310170850 ACCESSION NUMBER: 0001127602-21-010127 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210303 FILED AS OF DATE: 20210310 DATE AS OF CHANGE: 20210310 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mason Christopher CENTRAL INDEX KEY: 0001836440 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38537 FILM NUMBER: 21730685 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVROBIO, Inc. CENTRAL INDEX KEY: 0001681087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 810710585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 300, SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7819626030 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 300, SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AvroBio, Inc. DATE OF NAME CHANGE: 20160729 3 1 form3.xml PRIMARY DOCUMENT X0206 3 2021-03-03 0 0001681087 AVROBIO, Inc. AVRO 0001836440 Mason Christopher C/O AVROBIO, INC. ONE KENDALL SQUARE, BLDG. 300, SUITE 201 CAMBRIDGE MA 02139 1 Chief Scientific Officer Common Stock 284365 D Stock Option (Right to Buy) .41 2026-04-12 Common Stock 70587 D Stock Option (Right to Buy) 1.20 2026-10-24 Common Stock 27658 D Stock Option (Right to Buy) .91 2027-06-12 Common Stock 21708 D Stock Option (Right to Buy) 5.00 2028-03-15 Common Stock 29633 D Stock Option (Right to Buy) 16.98 2029-02-24 Common Stock 50000 D Stock Option (Right to Buy) 21.44 2030-03-03 Common Stock 76000 D Stock Option (Right to Buy) 16.02 2031-02-03 Common Stock 125000 D 25% of the shares vested on July 1, 2017, and the remaining 75% vested in equal quarterly installments thereafter over a three-year period. 25% of the shares vested on October 25, 2017, and the remaining 75% vested in equal quarterly installments thereafter over a three-year period. 25% of the shares vested on June 13, 2018, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period. 25% of the shares vested on March 16, 2019, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period. 25% of the shares vested on February 25, 2020, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period. 25% of the shares vested on February 3, 2021, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period. 25% of the shares shall vest on February 4, 2022, and the remaining 75% shall vest in equal quarterly installments thereafter over a three-year period. Exhibit 24 - Power of Attorney /s/ Christopher Gerry, Attorney in Fact for Christopher Mason 2021-03-10 EX-24 2 doc1.txt POWER OF ATTORNEY (PUBLIC): POWER OF ATTORNEY LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Steven Avruch, Christopher Gerry, Marcia Gookin, Arthur R. McGivern, and James Xu, signing singly, and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of AVROBIO, Inc. (the "Company"), from time to time the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID, including any attached documents (such as Update Passphrase Authentication), to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedules 13D and 13G and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedules 13D and 13G or any amendment(s) thereto, and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorneys-in- fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of, or legal counsel to, the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of March 4, 2021. _/s/ Christopher Mason _____ Name: Christopher Mason